Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 per share.
Appears in 3 contracts
Samples: Agreement and Plan of Merger (Spyre Therapeutics, Inc.), Agreement and Plan of Merger (Aeglea BioTherapeutics, Inc.), Agreement and Plan of Merger (Aeglea BioTherapeutics, Inc.)
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A C Non-Voting Convertible Preferred Stock (the “Series A C Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,34120,000. Each share of Series A C Non-Voting Preferred Stock shall have a par value of $0.0001 0.01 per share.
Appears in 1 contract
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341548,375. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 per share.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Selecta Biosciences Inc)
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A X Non-Voting Convertible Preferred Stock (the “Series A Non-Voting X Preferred Stock”) and the number of shares so designated shall be 1,086,3415. Each share of Series A Non-Voting X Preferred Stock shall have a par value of $0.0001 0.01 per share.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Idera Pharmaceuticals, Inc.)
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341435,000. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.01 per share.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Miragen Therapeutics, Inc.)
Designation, Amount and Par Value. The A series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Series A Preferred Stock (the “"Series A Non-Voting Preferred Stock”) "), and the number of shares so designated shall be 1,086,34115,507. The par value of each share of Series A Preferred Stock shall be $0.001 par value. Each share of Series A Non-Voting Preferred Stock shall have a par stated value of $0.0001 32.25 per shareshare (the "Stated Value").
Appears in 1 contract
Samples: Settlement Agreement and Mutual General Release (Incomnet Inc)
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A X Non-Voting Convertible Preferred Stock (the “Series A X Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341[•]. Each share of Series A X Non-Voting Preferred Stock shall have a par value of $0.0001 0.01 per share.
Appears in 1 contract
Designation, Amount and Par Value. The There shall be a series of Preferred Stock that shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock” (the “Series A Preferred Stock”) and the number of shares so designated constituting such series shall be 1,086,341[●]. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share. The shares of Series A Preferred Stock shall only be issued and maintained in the form of securities held in book-entry form.
Appears in 1 contract
Samples: Arrangement Agreement (Torchlight Energy Resources Inc)
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,3412,950,000. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share. The shares of Series A Non-Voting Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the DTC or its nominee shall initially be the sole registered holder of the shares of Series A Non-Voting Preferred Stock.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Aprea Therapeutics, Inc.)
Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341164,000. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share. The shares of Series A Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company (“DTC”) or its nominee shall initially be the sole registered holder of the shares of Series A Preferred Stock.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Unum Therapeutics Inc.)
